Finance

Beta
Lists
ALKS:NASDAQ
Alkermes Plc
$52.44
-4.79%
(-2.64) 1D
Jun 29, 3:19:58 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ALKS...
Open
$53.94
High
$54.45
Low
$52.36
Mkt. cap
8.74B
Avg. vol.
2.46M
Volume
1.67M
P/E ratio
58.31
52-wk high
$55.27
52-wk low
$25.16
EPS
$0.90
Beta
0.35
Shares outstanding
166.68M
No. of employees
2K
Open
$53.94
High
$54.45
Low
$52.36
Mkt. cap
8.74B
Avg. vol.
2.46M
Volume
1.67M
P/E ratio
58.31
52-wk high
$55.27
52-wk low
$25.16
EPS
$0.90
Beta
0.35
Shares outstanding
166.68M
No. of employees
2K
News stories
From sources across the web
Profile
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies, the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio. Wikipedia
About Alkermes Plc
CEORichard F. Pops | Richard F. Pops
Employees2.05K
Founded1987
Headquarters-
SectorBiotechnology
Websitealkermes.com
Analyst ratings
Based on 13 analysts giving stock ratings to ALKS in the past 3 months
Buy
Buy
10
Hold
2
Sell
1
12-month forecast
Based on 13 Wall Street analysts offering 12 month price targets for ALKS in the last 3 months.
Highest
Current $52.44
$65.00 (+23.95%)
Average
$50.75 (-3.22%)
Lowest
$38.00 (-27.54%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jason Gerberry
Bank of America Securities
Sell
Downgraded
$38.00
-27.5%
06/29/2026
Benjamin Burnett
Wells Fargo
Buy
Reiterated
$65.00
+24%
06/29/2026
Ami Fadia
Needham
Buy
Reiterated
$61.00
+16.3%
06/24/2026
David Amsellem
Piper Sandler
Buy
Reiterated
$43.00
-18%
06/22/2026
Joseph Thome
TD Cowen
Buy
Reiterated
$50.00
-4.7%
06/22/2026
Akash Tewari
Jefferies
Buy
Maintained
$59.00
+12.5%
06/18/2026
Douglas Tsao
H.C. Wainwright
Hold
Reiterated
$43.00
-18%
06/18/2026
Uy Ear
Mizuho Securities
Buy
Reiterated
$53.00
+1.1%
06/09/2026
Leonid Timashev
RBC Capital
Buy
Maintained
$56.00
+6.8%
06/08/2026
Luke Herrmann
Robert W. Baird
Buy
Maintained
$48.00
-8.5%
05/13/2026
Unknown Analyst
Wells Fargo
Buy
Maintained
$44.00
-16.1%
05/13/2026
Paul Matteis
Stifel Nicolaus
Buy
Maintained
$45.00
-14.2%
05/08/2026
Ashwani Verma
UBS
Buy
Maintained
$48.00
-8.5%
05/06/2026
Marc Goodman
Leerink Partners
Hold
Maintained
-
-
03/31/2026
Pete Stavropoulos
Cantor Fitzgerald
Buy
Maintained
$43.00
-18%
03/11/2026
Joon Lee
Truist Financial
Buy
Maintained
-
-
02/26/2026
Rudy Li
Wolfe Research
Buy
Initiated
$45.00
-14.2%
02/23/2026
Last report
May 5, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
$0.38 / -$0.04
+1,053.00%beat
Revenue / Est. (USD)
392.91M / 361.38M
+8.73%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
390.66M
394.18M
384.55M
392.91M
Cost of goods sold
49.46M
51.59M
46.21M
48.85M
Cost of revenue
49.46M
51.59M
46.21M
48.85M
Research and development expenses
74.07M
78.54M
89.74M
100.08M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
174.15M
174.97M
190.50M
233.06M
Operating expense
248.22M
253.51M
280.23M
344.81M
Total operating expenses
297.68M
305.10M
326.44M
393.66M
Operating income
92.98M
89.08M
58.10M
-754.00K
Other non operating income
771.00K
-280.00K
1.42M
-1.29M
EBT including unusual items
104.84M
100.74M
60.38M
-61.93M
EBT excluding unusual items
104.84M
100.74M
60.38M
-14.40M
Income tax expense
17.74M
17.98M
11.04M
4.55M
Effective tax rate
16.92%
17.85%
18.28%
-7.35%
Other operating expenses
-
-
-
-
Net income
87.10M
82.76M
49.34M
-66.48M
Net profit margin
22.30%
21.00%
12.83%
-16.92%
Earnings per share
0.68
0.65
0.48
0.38
Interest and investment income
11.09M
11.94M
12.13M
8.54M
Interest expense
-
-
-12.28M
-20.89M
Net interest expenses
11.09M
11.94M
-147.00K
-12.35M
Depreciation and amortization charges
-
-
-
-
EBITDA
100.80M
97.16M
61.95M
18.68M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer